ZYUS Life Sciences Corporation
ZLSCF
$0.59
-$0.0501-7.83%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.49% | 34.95% | 36.13% | 34.60% | 22.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.49% | 34.95% | 36.13% | 34.60% | 22.34% |
| Cost of Revenue | -41.50% | -40.57% | 260.32% | 280.18% | 281.07% |
| Gross Profit | 53.60% | 53.87% | -487.63% | -529.43% | -548.94% |
| SG&A Expenses | -30.47% | -27.86% | 5.75% | 18.90% | 46.99% |
| Depreciation & Amortization | -1.82% | -6.09% | -3.40% | -12.13% | -27.00% |
| Other Operating Expenses | 32.99% | 36.35% | 38.31% | 7.65% | 23.82% |
| Total Operating Expenses | -19.54% | -19.40% | 21.79% | 24.03% | 30.01% |
| Operating Income | 20.33% | 20.38% | -21.48% | -23.82% | -30.18% |
| Income Before Tax | 24.78% | 27.83% | -72.76% | -53.04% | -90.80% |
| Income Tax Expenses | 65.58% | 65.28% | -9,702.05% | -10,353.77% | -10,542.82% |
| Earnings from Continuing Operations | 19.02% | 22.73% | -49.32% | -32.38% | -67.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.02% | 22.73% | -49.32% | -32.38% | -67.59% |
| EBIT | 20.33% | 20.38% | -21.48% | -23.82% | -30.18% |
| EBITDA | 22.77% | 22.30% | -26.00% | -32.16% | -47.94% |
| EPS Basic | 31.12% | 38.85% | 5.27% | 23.30% | -3.16% |
| Normalized Basic EPS | 42.46% | 52.30% | 39.03% | 46.33% | 30.38% |
| EPS Diluted | 31.31% | 38.31% | 3.93% | 22.22% | -3.96% |
| Normalized Diluted EPS | 42.46% | 52.30% | 39.03% | 46.33% | 30.38% |
| Average Basic Shares Outstanding | 13.77% | 28.60% | 47.39% | 74.51% | 66.39% |
| Average Diluted Shares Outstanding | 13.77% | 28.60% | 47.39% | 74.51% | 66.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |